MTOR and breast carcinoma: N68 has also been tested in clinical trials for early (Phase 2) and late breast cancer (Phase 1b).16 Finally, Voxtalisib (CAS 934493-76-2) (103), a kinase inhibitor of PI3K and mammalian target of rapamycin in the PI3K/mTOR signaling cascade was patented by Exelis (XL-765) in 2006.